Stock 2256 ABBISKO CAYMAN LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Abbisko Cayman Limited Stock

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 EDT 		5-day change 1st Jan Change
3.28 HKD +4.79% Intraday chart for Abbisko Cayman Limited +13.10% -10.14%
04-25 Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation MT
04-24 Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary CI

Financials

Sales 2024 * 168M 23.19M 182M 31.7M Sales 2025 * 255M 35.16M 275M 48.06M Capitalization 1.77B 245M 1.92B 335M
Net income 2024 * -517M -71.35M -559M -97.54M Net income 2025 * -785M -108M -848M -148M EV / Sales 2024 * -0.92 x
Net cash position 2024 * 1.93B 266M 2.08B 364M Net cash position 2025 * 1.39B 191M 1.5B 261M EV / Sales 2025 * 1.52 x
P/E ratio 2024 *
-3.7 x
P/E ratio 2025 *
-3.23 x
Employees 258
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.44%
More Fundamentals * Assessed data

Chart Abbisko Cayman Limited

Dynamic Chart

Latest news about Abbisko Cayman Limited

Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation MT
Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary CI
Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting MT
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment MT
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib CI
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise MT
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares MT
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023. CI
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment MT
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment MT
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme MT
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug MT
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3% MT
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051 CI
More news

Press releases Abbisko Cayman Limited

Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021） PR
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck PR
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061 PR
Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules PR
Abbisko Cayman : Qiming's Portfolio Company Abbisko Lists on Main Board of HKEx PR
More press releases

Quotes and Performance

1 day+4.79%
1 week+13.10%
Current month+13.89%
1 month+14.69%
3 months+28.63%
6 months+26.15%
Current year-10.14%
More quotes

Highs and lows

1 week
2.91
Extreme 2.91
3.28
1 month
2.71
Extreme 2.71
3.28
Current year
2.05
Extreme 2.05
3.64
1 year
2.05
Extreme 2.05
4.69
3 years
2.05
Extreme 2.05
12.54
5 years
2.05
Extreme 2.05
12.54
10 years
2.05
Extreme 2.05
12.54
More quotes

Managers and Directors - Abbisko Cayman Limited

Managers TitleAgeSince
Zhui Chen FOU
 Founder 49 16-04-11
Yao Chang Xu CEO
 Chief Executive Officer 67 16-04-11
Hong Ping Yu FOU
 Founder 56 16-04-11
Members of the board TitleAgeSince
Hong Bin Sun BRD
 Director/Board Member 48 21-09-29
Piao Yang Sun BRD
 Director/Board Member 65 21-09-29
Hong Ping Yu FOU
 Founder 56 16-04-11
More insiders

Quotes

Date Price Change Volume
24-04-26 3.28 +4.79% 1,534,000
24-04-25 3.13 +0.64% 670,000
24-04-24 3.11 +1.97% 902,000
24-04-23 3.05 +1.33% 1,283,607
24-04-22 3.01 +3.79% 1,626,000

Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am

More quotes

Company Profile

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).
Sector
Biotechnology & Medical Research
Calendar
2024-08-18 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Abbisko Cayman Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.036 CNY
Average target price
7.572 CNY
Spread / Average Target
+149.37%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ABBISKO CAYMAN LIMITED Stock Abbisko Cayman Limited
-10.14% 245M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2256 Stock